Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

被引：50

作者：

Mack, PC ^{[1
]}

Davies, AM ^{[1
]}

Lara, PN ^{[1
]}

Gumerlock, PH ^{[1
]}

Gandara, DR ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Canc, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA

来源：

LUNG CANCER | 2003年 / 41卷

关键词：

lung cancer; PS-341; proteasome inhibitor;

D O I：

10.1016/S0169-5002(03)00149-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS-341, a potent and selective proteasome inhibitor, is the prototype for a new class of therapeutics that targets the ubiquitin - proteasome pathway. It is active as a single agent and potentiates chemotherapy and radiation in pre-clinical models. Early phase clinical studies have demonstrated tolerability and activity in multiple myeloma, lymphoma, prostate cancer and lung cancer. By its mechanism of inhibiting protein degradation, PS-341 targets a wide-range of pathways that are relevant to tumor progression and therapy resistance, and can directly modulate expression of cyclins, p27(Kip1), p53, NF-kappaB, Bcl-2 and Bax. PS-341 is currently in phase I/II clinical development in lung cancer. This paper wilt review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer. (C) 2003 Elsevier Science Ireland Ltd and American Society of Clinical Oncology. Published by Elsevier Science Ireland Ltd. All. rights reserved.

引用

页码：S89 / S96

页数：8

共 50 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2] Development of the proteasome inhibitor PS-341 [J].

Adams, J .

ONCOLOGIST, 2002, 7 (01) :9-16

[3] Proteasome inhibition: a new strategy in cancer treatment [J].

Adams, J ;

Palombella, VJ ;

Elliott, PJ .

INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) :109-121

[4]

AGHAJANIAN C, 2001, P AM SOC CLIN ONCOL

[5] Protease inhibitor-induced apoptosis:: accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition [J].

An, WG ;

Hwang, SG ;

Trepel, JB ;

Blagosklonny, MV .

LEUKEMIA, 2000, 14 (07) :1276-1283

[6] P53: An ubiquitous target of anticancer drugs [J].

Blagosklonny, MV .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :161-166

[7] Proteasome-dependent regulation of p21(WAF1/CIP1) expression [J].

Blagosklonny, MV ;

Wu, GS ;

Omura, S ;

ElDeiry, WS .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 227 (02) :564-569

[8] Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content [J].

Bold, RJ ;

Chandra, J ;

McConkey, DJ .

ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (03) :279-285

[9] Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome [J].

Bold, RJ ;

Virudachalam, S ;

McConkey, DJ .

JOURNAL OF SURGICAL RESEARCH, 2001, 100 (01) :11-17

[10] Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer [J].

Borner, MM ;

Brousset, P ;

Pfanner-Meyer, B ;

Bacchi, M ;

Vonlanthen, S ;

Hotz, MA ;

Altermatt, HJ ;

Schlaifer, D ;

Reed, JC ;

Betticher, DC .

BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) :952-958

← 1 2 3 4 5 →